AAPL 258.8189 0.2397% MSFT 439.14 -0.0432% NVDA 140.185 -0.025% GOOGL 196.0128 -0.0496% GOOG 197.54 -0.0152% AMZN 227.87 -0.5152% META 603.74 -0.6598% AVGO 245.6915 2.5081% TSLA 452.9125 -2.0264% TSM 204.19 -1.0372% LLY 797.2122 0.1938% V 320.96 0.0967% JPM 242.37 0.0248% UNH 509.62 0.6955% NVO 87.85 0.5494% WMT 92.38 -0.3237% LVMUY 132.91 0.4459% XOM 106.31 -0.0846% LVMHF 664.0 0.9119% MA 536.2159 0.0944%

Raia Drogasil SA ADR

Healthcare US RADLY

3.23USD
0.12(3.86%)

Last update at 2024-12-26T17:37:00Z

Day Range

3.233.23
LowHigh

52 Week Range

4.1713.65
LowHigh

Fundamentals

  • Previous Close 3.11
  • Market Cap10509.15M
  • Volume108
  • P/E Ratio47.15
  • Dividend Yield0.70%
  • EBITDA2609.73M
  • Revenue TTM32885.72M
  • Revenue Per Share TTM19.40
  • Gross Profit TTM 8809.47M
  • Diluted EPS TTM0.13

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1193.21M 987.26M 616.37M 784.17M 638.86M
Minority interest -18.85600M -12.19900M 62.49M 51.41M 34.91M
Net income 996.11M 751.93M 484.44M 772.24M 502.45M
Selling general administrative 1249.85M 912.33M 699.76M 548.71M 416.48M
Selling and marketing expenses 5805.99M 4966.82M 4256.42M 3754.77M 3261.90M
Gross profit 8809.47M 7206.17M 5891.13M 5198.36M 4445.52M
Reconciled depreciation 1515.54M 1327.11M 1177.28M 1041.03M 414.13M
Ebit 1479.92M 1222.39M 854.20M 785.08M 685.74M
Ebitda 2995.46M 2549.50M 2031.48M 1826.11M 1099.87M
Depreciation and amortization 1515.54M 1327.11M 1177.28M 1041.03M 414.13M
Non operating income net other - - - - -
Operating income 1479.92M 1222.39M 854.20M 785.08M 721.51M
Other operating expenses 27233.22M 22752.50M 19139.25M 16670.72M 14034.30M
Interest expense 292.69M 228.23M 234.09M 224.50M 1.25M
Tax provision 178.24M 223.13M 120.83M -4.56700M 129.54M
Interest income 0.49M 0.06M 0.00000M - 11.13M
Net interest income -673.91400M -388.72300M -313.27200M -341.37100M -92.75800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 178.24M 223.13M 120.83M -4.56700M 129.54M
Total revenue 29067.38M 24127.00M 20066.84M 17565.60M 14801.44M
Total operating expenses 6975.30M 5831.67M 4963.54M 4303.48M 3678.38M
Cost of revenue 20257.91M 16920.83M 14175.71M 12367.24M 10355.92M
Total other income expense net -286.71000M -235.12900M -237.82800M -0.90700M -82.65400M
Discontinued operations - - - - -
Net income from continuing ops 1014.97M 764.13M 495.53M 788.74M 509.31M
Net income applicable to common shares 996.11M 751.93M 484.44M 772.24M 502.45M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 17185.31M 14775.51M 13828.09M 12248.25M 7352.01M
Intangible assets 657.94M 526.48M 436.17M 419.91M 376.85M
Earning assets - - - - -
Other current assets 266.88M 290.81M 261.02M 244.43M 156.85M
Total liab 11782.36M 10056.70M 9402.47M 8171.84M 3817.24M
Total stockholder equity 5340.86M 4677.67M 4363.13M 4025.01M 3499.86M
Deferred long term liab - - - - -
Other current liab 1162.59M 926.59M 659.84M 629.94M 499.23M
Common stock 2500.00M 2500.00M 2500.00M 2500.00M 1808.64M
Capital stock 2500.00M 2500.00M 2500.00M 2500.00M 1808.64M
Retained earnings 2716.77M 2072.98M 1733.65M 1413.63M 1593.06M
Other liab 302.94M 295.39M 551.31M 577.55M 333.58M
Good will 1080.17M 959.77M 825.53M 825.53M 825.53M
Other assets 290.79M 239.91M 525.42M 432.51M 72.83M
Cash 433.54M 356.12M 880.36M 299.23M 241.57M
Cash and equivalents - - - - -
Total current liabilities 6367.17M 5896.19M 4801.30M 4078.49M 2913.45M
Current deferred revenue 890.92M 695.48M 497.16M 493.61M 357.86M
Net debt 5624.37M 4822.00M 4204.02M 4011.88M 601.58M
Short term debt 945.66M 1313.00M 1034.52M 795.31M 272.94M
Short long term debt 186.36M 613.83M 531.20M 228.66M 272.94M
Short long term debt total 6057.91M 5178.12M 5084.38M 4311.11M 843.15M
Other stockholder equity 2840.86M 2177.67M 1863.13M 1525.01M 1691.22M
Property plant equipment 5574.86M 5329.59M 5020.47M 4814.26M 1546.96M
Total current assets 9577.07M 7718.92M 7020.49M 5756.05M 4529.82M
Long term investments - - - - -
Net tangible assets 3602.75M 3191.42M 3101.42M 2779.57M 2297.47M
Short term investments - - - - -
Net receivables 2750.59M 1954.19M 1653.70M 1361.01M 1044.13M
Long term debt 2131.55M 891.39M 1122.25M 897.82M 570.21M
Inventory 6126.06M 5117.80M 4225.41M 3851.39M 3087.28M
Accounts payable 4258.92M 3656.61M 3106.94M 2653.24M 2141.27M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 284.91M 191.70M 489.16M 432.51M 72.83M
Deferred long term asset charges - - - - -
Non current assets total 7608.24M 7056.58M 6807.60M 6492.21M 2822.18M
Capital lease obligations 3740.01M 3672.90M 3430.93M 3184.63M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1229.58200M -12.63600M -3.28900M -3.28900M -3.28900M
Change to liabilities 611.54M 390.75M 456.03M 465.19M 318.45M
Total cashflows from investing activities -1229.58200M -885.95000M -673.09700M -2.74000M -702.96800M
Net borrowings -51.16800M -850.58200M -32.49200M -502.11200M 217.34M
Total cash from financing activities -375.25000M -1188.83400M -223.01000M -904.81300M -3.20300M
Change to operating activities 232.94M 245.15M 110.94M -202.61800M -6.98000M
Net income 1193.21M 987.26M 616.37M 784.17M 638.86M
Change in cash 77.42M -524.23900M 581.13M 57.66M -23.30500M
Begin period cash flow 356.12M 880.36M 299.23M 241.57M 264.87M
End period cash flow 433.54M 356.12M 880.36M 299.23M 241.57M
Total cash from operating activities 1682.26M 1550.55M 1477.24M 965.21M 682.87M
Issuance of capital stock - - - - -
Depreciation 1515.54M 1327.11M 1177.28M 1041.03M 414.13M
Other cashflows from investing activities -0.80000M -18.45000M -0.03500M -0.03500M -0.03500M
Dividends paid 324.08M 265.02M 190.52M 186.60M 173.62M
Change to inventory -1035.34100M -896.80900M -389.10000M -667.14700M -567.00100M
Change to account receivables -583.60200M -158.09200M -377.89500M -250.83400M 1.13M
Sale purchase of stock 0.00000M -73.22700M - - -46.92500M
Other cashflows from financing activities 293.24M -597.96100M 2.23M -442.16200M 245.60M
Change to netincome 100.63M -77.82000M 22.76M -386.03000M 88.10M
Capital expenditures 1188.78M 855.60M 676.42M 286.65M 702.99M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -934.66700M -455.00000M -294.04900M -680.84900M -323.44000M
Stock based compensation 22.60M 15.09M 18.09M 13.44M 12.52M
Other non cash items -114.42900M -323.91300M -40.45300M -192.58100M -59.19900M
Free cash flow 493.47M 694.95M 800.82M 678.57M -20.11900M

Peer Comparison

Sector: Healthcare Industry: Pharmaceutical Retailers

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RADLY
Raia Drogasil SA ADR
0.12 3.86% 3.23 47.15 32.68 0.34 9.83 0.35 3.29
WBA
Walgreens Boots Alliance Inc
0.42 4.62% 9.62 - 5.40 0.11 1.14 0.33 -4.3066
ALBHF
Alibaba Health Information Technology Limited
0.005 1.14% 0.45 50.80 29.59 0.30 3.62 1.58 34.83
ALBBY
Alibaba Health Information Technology Limited
0.04 0.50% 8.98 48.10 30.30 0.29 3.70 1.58 34.83
SHPPF
Shop Apotheke Europe N.V
-20.84 13.03% 139.16 - - 2.80 2.28 1.70 78.78

Reports Covered

Stock Research & News

Profile

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines in Brazil. It also markets its goods through telesales and call centers in the states of São Paulo, Tocantins, and Pernambuco. The company was founded in 1905 and is headquartered in São Paulo, Brazil.

Raia Drogasil SA ADR

Av. Corifeu de Azevedo Marques, 3097, São Paulo, SP, Brazil, 05.339-900

Key Executives

Name Title Year Born
Mr. Marcílio D'Amigo Pousada CEO & Member of Exec. Board 1965
Mr. Antonio Carlos Coelho VP of Fin. & Admin. and Member of Exec. Board NA
Mr. Eugênio De Zagottis VP of Corp. Planning, IR, M&A and Member of Exec. Board NA
Mr. Marcello De Zagottis VP of Commercial & Marketing and Member of Exec. Board NA
Mr. Fernando Kozel Varela VP of Digital Transformation & Member of Exec. Board NA
Mr. Renato Cepollina Raduan VP of Store, Multichannel & Expansion Operations and Member of Exec. Board NA
Ms. Maria Susana De Souza VP of People, Culture & Sustainability and Member of Exec. Board NA
Mr. Bruno Wright Pipponzi VP of Health Bus. & Member of Exec. Board NA
Ligia Maria Mendes Controllership Director & Accountant In charge NA
Gabriel Rozenberg IR & Corp. Planning Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.